Lennox 2001.

Study characteristics
Methods	Design: 3‐group randomized controlled trial Setting: 6 general practices in Aberdeen, UK Recruitment: Mailed lettered to patients identified in EMR
Participants	2553 people who smoked aged 17 ‐ 65, av. age not reported, av. cpd not reported
Interventions	Intervention 1: participants received an untailored letter on smoking cessation Intervention 2: participants received a tailored letter on smoking cessation Control: participants received a letter thanking them for participation and informing them that they would receive material at the end of the study (either a tailored or a non‐tailored letter)
Outcomes	7‐day PPA at 6m Validation: Salivary cotinine, cut‐off not reported (only completed in 3.5% of participants)
Funding Source	The Chief Scientist Office, Scottish Executive Health Department, with additional funding from the Engineering and Physical Sciences Research Council. The Health Economics Research Unit is funded by the Chief Scientist Office
Author's declarations of interest	Authors declared that they had no conflict of interest
Notes	Strategy: Tailored print materials Level: Patient Comparison type: Single component vs. standard care
Risk of bias
Bias	Authors' judgement	Support for judgement
Sequence Generation	Low risk	Computer‐generated random numbers were used
Allocation concealment	Unclear risk	No details reported
Blinding of outcome assessors All outcomes	Low risk	Salivary cotinine, cut‐off not reported (only completed in 3.5% of participants). Face‐to‐face contact was minimal in all groups
Incomplete outcome data All outcomes	Low risk	The overall loss to follow‐up was 23.6% (n = 615/2610); 24.5% (n = 213/870) in the tailored letter group, 27.2% (n = 236/869) in the standard letter group and 19.1% (n = 166/871) in the control group were lost to follow‐up at 6 months